TY - JOUR
TI - Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial: Effects of Elamipretide in Heart Failure
AU - Butler, J.
AU - Khan, M.S.
AU - Anker, S.D.
AU - Fonarow, G.C.
AU - Kim, R.J.
AU - Nodari, S.
AU - O'Connor, C.M.
AU - Pieske, B.
AU - Pieske-Kraigher, E.
AU - Sabbah, H.N.
AU - Senni, M.
AU - Voors, A.A.
AU - Udelson, J.E.
AU - Carr, J.
AU - Gheorghiade, M.
AU - Filippatos, G.
JO - Journal of Cardiac Failure
PY - 2020
VL - 26
TODO - 5
SP - 429-437
PB - Churchill Livingstone Inc.
SN - 1071-9164, 1532-8414
TODO - 10.1016/j.cardfail.2020.02.001
TODO - diuretic agent;  elamipretide;  gadolinium;  placebo;  arginyl-2,'6'-dimethyltyrosyl-lysyl-phenylalaninamide;  oligopeptide, adult;  aged;  Article;  cardiovascular magnetic resonance;  controlled study;  double blind procedure;  drug dose comparison;  drug withdrawal;  echocardiography;  fatigue;  female;  follow up;  heart failure with reduced ejection fraction;  heart left ventricle endsystolic volume;  heart left ventricle function;  human;  injection site reaction;  major clinical study;  male;  nausea;  phase 2 clinical trial;  priority journal;  randomized controlled trial;  side effect;  clinical trial;  heart failure;  heart stroke volume;  middle aged, Aged;  Female;  Heart Failure;  Humans;  Middle Aged;  Oligopeptides;  Stroke Volume;  Ventricular Function, Left
TODO - Background: Elamipretide, a novel mitochondrial modulating agent, improves myocardial energetics; however, it is unknown whether this mechanistic benefit translates into improved cardiac structure and function in heart failure (HF) with reduced ejection fraction (HFrEF). The objective of this study was to evaluate the effects of multiple subcutaneous doses of elamipretide on left ventricular end systolic volume (LVESV) as assessed by cardiac magnetic resonance imaging. Methods: We randomized 71 patients with HFrEF (LVEF ≤ 40%) in a double-blind, placebo-controlled trial in a 1:1:1 ratio to receive placebo, 4 mg or 40 mg elamipretide once daily for 28 consecutive days. Results: The mean age (standard deviation) of the study population was 65 ± 10 years, 24% were females, and the mean EF was 31% ± 7%. The change in LVESV from baseline to week 4 was not significantly different between elamipretide 4 mg (89.4 mL to 85 mL; difference, −4.4 mL) or 40 mg (77.9 mL to 76.6 mL; difference, −1.2 mL) compared with placebo (77.7 mL to 74.6 mL; difference, −3.8 mL) (4 mg vs placebo: difference of means, −0.3; 95% CI, −4.6 to 4.0; P = 0.90; and 40 mg vs placebo: difference of means, 2.3; 95% CI, −1.9 to 6.5; P = 0.28). Also, no significant differences in change in LVESV and LVEF were observed between placebo and either of the elamipretide groups. Rates of any study drug-related adverse events were similar in the 3 groups. Conclusions: Elamipretide was well tolerated but did not improve LVESV at 4 weeks in patients with stable HFrEF compared with placebo. © 2020
ER -